KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to 38.56%.

  • Vertex Pharmaceuticals' EBITDA Margin fell 17100.0% to 38.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 34.06%, marking a year-over-year increase of 366100.0%. This contributed to the annual value of 2.11% for FY2024, which is 409400.0% down from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported EBITDA Margin of 38.56% as of Q3 2025, which was down 17100.0% from 38.83% recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' EBITDA Margin ranged from a high of 53.15% in Q3 2021 and a low of 132.85% during Q2 2024
  • Moreover, its 5-year median value for EBITDA Margin was 41.17% (2023), whereas its average is 30.43%.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' EBITDA Margin crashed by -1740200bps in 2024, and later soared by 1716800bps in 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' EBITDA Margin (Quarter) stood at 42.35% in 2021, then rose by 6bps to 44.88% in 2022, then decreased by -13bps to 39.26% in 2023, then dropped by -10bps to 35.23% in 2024, then rose by 9bps to 38.56% in 2025.
  • Its last three reported values are 38.56% in Q3 2025, 38.83% for Q2 2025, and 22.75% during Q1 2025.